Login to Your Account



Limited Indication Plan B

Vivus Plans New Study, 4Q Qnexa NDA Resubmission

By Tom Wall


Wednesday, May 4, 2011
One way or the other, Mountain View, Calif.-based Vivus Inc. expects to resubmit a new drug application (NDA) for obesity drug Qnexa (phentermine/topiramate) in the fourth quarter.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription